Isozid N

Isoniazid, the active ingredient in Isozid N, is an antitubercular agent presented as an intravenous formulation for intravenous use. It treats active tuberculosis and is used for prevention of tuberculosis in high‑risk individuals.

GNH USA supplies Isozid N as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide, with a focus on quality assurance, regulatory compliance, and reliable global logistics. The company adheres to stringent manufacturing standards and provides comprehensive support for product registration and import documentation.

Isoniazid is an antitubercular agent used in the management of Mycobacterium tuberculosis infection.

- Active pulmonary tuberculosis: contributes to bacterial eradication as part of combination therapy. - Latent tuberculosis infection: reduces risk of progression to active disease. - High‑risk exposure prophylaxis: prevents development of active tuberculosis in contacts.

Isoniazid may cause a range of adverse reactions.

Common Side Effects: - Nausea or vomiting - Loss of appetite - Peripheral neuropathy (tingling or numbness) - Skin rash

Serious or Rare Side Effects: - Hepatotoxicity (elevated liver enzymes, hepatitis) - Severe allergic reactions (anaphylaxis, Stevens‑Johnson syndrome) - Sideroblastic anemia - Drug‑induced lupus‑like syndrome

When using Isozid N, several safety considerations are recommended.

- Liver function monitoring: assess baseline and periodic liver enzymes due to risk of hepatotoxicity. - Alcohol consumption: avoid or limit alcohol as it increases liver toxicity. - Vitamin B6 supplementation: consider pyridoxine to prevent peripheral neuropathy, especially in malnourished or diabetic patients. - Pregnancy: use only if benefits outweigh risks; classified as Category C. - Age considerations: dose adjustment may be needed in elderly or renal impairment. - Store at room temperature: keep in original container, protect from moisture and light.

Isoniazid can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Rifampin: may lower isoniazid plasma levels, reducing effectiveness. - Carbamazepine or phenytoin: hepatic enzyme induction can decrease isoniazid concentrations. - Alcohol: combined use heightens risk of liver injury.

Moderate Interactions (Monitor Closely): - Warfarin: isoniazid may potentiate anticoagulant effect, requiring INR monitoring. - Oral contraceptives: efficacy may be reduced, consider alternative contraception. - Zidovudine: concurrent use can increase zidovudine toxicity.